Merrimack Pharma Caps $37.3 Million in Financing

Merrimack Pharmaceuticals Inc. said Wednesday it has completed equity and debt financings totaling $37.3 million. According to the Cambridge drug company, the financing was made up of a $28.3 million of Series D preferred stock and a $9 million venture loan.

Boston Business Journal (http://www.bizjournals.com/boston/stories/2005/04/18/daily37.html)